| Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study L Kappos, A Bar-Or, BAC Cree, RJ Fox, G Giovannoni, R Gold, ... The Lancet 391 (10127), 1263-1273, 2018 | 939 | 2018 |
| Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage M Filippi, MA Rocca, E Pagani, N De Stefano, D Jeffery, L Kappos, ... Journal of Neurology, Neurosurgery & Psychiatry 85 (8), 851-858, 2014 | 139 | 2014 |
| Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS: Patient management considerations RJ Fox, A Chan, R Gold, JT Phillips, K Selmaj, I Chang, M Novas, J Rana, ... Neurology: Clinical Practice 6 (3), 220-229, 2016 | 107 | 2016 |
| Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study DH Miller, RJ Fox, JT Phillips, M Hutchinson, E Havrdova, M Kita, ... Neurology 84 (11), 1145-1152, 2015 | 81 | 2015 |
| Reviewing the significance of blood–brain barrier disruption in multiple sclerosis pathology and treatment R Balasa, L Barcutean, O Mosora, D Manu International Journal of Molecular Sciences 22 (16), 8370, 2021 | 79 | 2021 |
| The action of TH17 cells on blood brain barrier in multiple sclerosis and experimental autoimmune encephalomyelitis R Balasa, L Barcutean, A Balasa, A Motataianu, C Roman-Filip, D Manu Human immunology 81 (5), 237-243, 2020 | 77 | 2020 |
| Cardiac autonomic neuropathy in type 1 and type 2 diabetes patients A Moţăţăianu, S Maier, Z Bajko, S Voidazan, R Bălaşa, A Stoian BMC neurology 18, 1-9, 2018 | 60 | 2018 |
| Influence of GSTM1, GSTT1, and GSTP1 polymorphisms on type 2 diabetes mellitus and diabetic sensorimotor peripheral neuropathy risk A Stoian, C Bănescu, RI Bălaşa, A Moţăţăianu, M Stoian, VG Moldovan, ... Disease markers 2015, 2015 | 47 | 2015 |
| Predicting functional outcome of ischemic stroke patients in Romania based on plasma CRP, sTNFR-1, D-Dimers, NGAL and NSE measured using a biochip array A Huţanu, M Iancu, R Bălaşa, S Maier, M Dobreanu Acta pharmacologica sinica 39 (7), 1228-1236, 2018 | 46 | 2018 |
| Serum levels of IL-17A in patients with relapsing–remitting multiple sclerosis treated with interferon-β R Bălaşa, Z Bajko, A Huţanu Multiple sclerosis journal 19 (7), 885-890, 2013 | 46 | 2013 |
| Risk for major bleeding in patients receiving ticagrelor compared with aspirin after transient ischemic attack or acute ischemic stroke in the SOCRATES study (Acute Stroke or … JD Easton, M Aunes, GW Albers, P Amarenco, S Bokelund-Singh, ... Circulation 136 (10), 907-916, 2017 | 35 | 2017 |
| Cardiovascular autonomic neuropathy in context of other complications of type 2 diabetes mellitus A Moţăţăianu, R Bălaşa, S Voidăzan, Z Bajkó BioMed research international 2013, 2013 | 34 | 2013 |
| Autoimmune encephalitis in COVID-19 infection: our experience and systematic review of the literature A Stoian, M Stoian, Z Bajko, S Maier, S Andone, RA Cioflinc, A Motataianu, ... Biomedicines 10 (4), 774, 2022 | 32 | 2022 |
| Dysfunction of the neurovascular unit in ischemic stroke: highlights on microRNAs and exosomes as potential biomarkers and therapy T Forró, Z Bajkó, A Bălașa, R Bălașa International Journal of Molecular Sciences 22 (11), 5621, 2021 | 26 | 2021 |
| Ticagrelor added to aspirin in acute ischemic stroke or transient ischemic attack in prevention of disabling stroke: a randomized clinical trial P Amarenco, H Denison, SR Evans, A Himmelmann, S James, ... JAMA neurology 78 (2), 177-185, 2021 | 26 | 2021 |
| A phase 3 multicenter, prospective, open-label efficacy and safety study of immune globulin (human) 10% caprylate/chromatography purified in patients with myasthenia gravis … G Karelis, R Balasa, JL De Bleecker, T Stuchevskaya, A Villa, ... European Neurology 81 (5-6), 223-230, 2019 | 26 | 2019 |
| Oxidative stress in amyotrophic lateral sclerosis: synergy of genetic and environmental factors A Motataianu, G Serban, L Barcutean, R Balasa International Journal of Molecular Sciences 23 (16), 9339, 2022 | 25 | 2022 |
| The impact of CYP2C19 loss-of-function polymorphisms, clinical, and demographic variables on platelet response to clopidogrel evaluated using impedance aggregometry A Mărginean, C Bănescu, V Moldovan, A Scridon, M Mărginean, R Bălaşa, ... Clinical and Applied Thrombosis/Hemostasis 23 (3), 255-265, 2017 | 25 | 2017 |
| Depression in multiple sclerosis-review S Maier, R Balasa, M Buruian, A Maier, Z Bajko Romanian Journal of Neurology 14 (1), 22-29, 2015 | 25 | 2015 |
| Common carotid artery occlusion: a case series Z Bajkó, R Bălaşa, A Moţăţăianu, S Maier, OC Chebuţ, S Szatmári International Scholarly Research Notices 2013, 2013 | 25 | 2013 |
